This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This page discusses the common questions transplant professionals as well as transplant patients may have with COVID-19. We have few facts and little evidence, and those are laid out below. Locally, the decisions being taken depend on local resources, logistics and other factors, and hence local practice may appropriately vary.
Iodinated contrast is well known to cause acute kidney injury (AKI), mainly from its physico-chemical properties, and is the commonly cited as being the third most common cause of AKI in hospitalized patients. But is this really true? Even the term contrast-induced AKI (CI-AKI) is now being increasingly replaced by contrast-associated AKI (CA-AKI), and could contrast be an 'innocent bystander'?
